Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 802 results for "eisai"

Eisai, Arena Pharmaceuticals Get Regulatory Approval For VENES...

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) and Eisai Inc. revealed Thursday that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has given its approval for the chronic weight management agent VENESPRI. It would proceed ... Benzinga.com, 1 week ago

81 images for eisai

BioSpace, 1 week ago
Bio Spectrum Asia, 10 hours ago
BioSpace, 10 hours ago
Pharma Letter, 1 week ago
Business Insider, 2 weeks ago
Reuters UK, 2 weeks ago
Nasdaq, 1 week ago
CPhI.cn, 2 weeks ago
Broadcast Newsroom, 3 weeks ago
SRN News, 2 weeks ago
BioSpace

Arena - Anti-Obesity Drug Lorcaserin Approved In Mexico

Arena Pharmaceuticals (NASDAQ: ARNA ) and its marketing partner Eisai ( OTCPK:ESALY ) have announced that the anti-obesity drug Lorcaserin has been approved in Mexico . Lorcaserin is marketed as Belviq in the United States and South Korea, but will ...
 Seeking Alpha1 week ago Eisai and Arena Pharmaceuticals secure regulatory approval of VENESPRI in Mexico  Pharmaceutical Business Review1 week ago Obesity drug Venespri (Belviq) approved in Mexico  Pharma Letter1 week ago Eisai and Arena Pharmaceuticals Announce Regulatory Approval of VENESPRI ® (lorcaserin HCl) in Mexico  Stockwatch1 week ago
[x]  
APN News

Eisai : listed for 15th Consecutive Year FTSE4Good Index Series, an Index for Socially Responsible Investment

- (ACN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been included in the FTSE4Good Index Series for the 15th consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series ...
 4 Traders3 weeks ago Eisai listed for 15th Consecutive Year FTSE4Good Index Series, an Index for Socially Responsible Investment  Benzinga.com3 weeks ago Eisai launches U.S. Fycompa oral suspension for patients with swallowing problems  FiercePharma1 month ago Ncomputing announces MX100 3 User Thin Client Kit For Less Than 1/3 The Cost Of A PC Based Solution  APN News1 month ago
[x]  
WorldNetDaily

Lenvatinib Approved for Use with Everolimus for Treating Advanced Renal Cell Carcinoma

, the U. S. Food and Drug Administration approved lenvatinib capsules (Lenvima, Eisai, Inc.), in combination with everolimus, for the treatment of advanced renal cell carcinoma following one prior anti-angiogenic therapy.Lenvatinib was first ...
 OncologyNurse.com2 weeks ago BRIEF-R&I affirms Eisais rating at "A+" and stable outlook  Reuters UK2 weeks ago Eisai Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day  WorldNetDaily3 weeks ago EISAI : Highlights its Strong Pipeline and Innovative Approach to R&D at Company's U.S. Scientific Day  4 Traders3 weeks ago
[x]  
Pharmafile

Eisai introduces in-house developed anticancer agent Lenvima in Mexico

Eisai Co., Ltd. announced that its pharmaceutical sales subsidiary in Mexico, Eisai Laboratorios, S. de R.L. de C.V. has launched its in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in Mexico. Discovered at Eisai's Tsukuba ...
 PharmaBiz3 weeks ago Eisai launches cancer drug Lenvatinib in Mexico  Pharmafile3 weeks ago Eisai Launches In-House Developed Novel Anticancer Agent Lenvima In Mexico  FirstWord Pharma3 weeks ago
Moneycontrol.com

Actavis launches Donepezil in eight EU markets

17-Feb-2012 Europe | Generics Icelandic generics group Actavis has launched Donepezil, a generic version of Eisai and Pfizer's drug Aricept, in some of Europe's biggest markets, following patent expiry in the UK and Sweden. The conventional ...
 Manufacturing Chemist2 weeks ago Unichem receives approval for donepezil hydrochloride tablets  Business Standard India1 month ago Unichem Lab gets USFDA nod for Donepezil HCl tablets  Myiris4 weeks ago Unichem Laboratories surges on receiving ANDA approval for Donepezil Hydrochloride Tablets  Finalaya.com4 weeks ago
[x]  
CPhI.cn

Eisai chief pledges to subsidize thyroid cancer drug in CDF fight

The head of Eisai in Europe has pledged to subsidize the cost of thyroid cancer drug
 Pharma Letter1 week ago Eisai calls for immediate solution to CDF black hole  CPhI.cn2 weeks ago Patients denied thyroid cancer drug in England  pharmaphorum2 weeks ago Anger at exclusion of Eisai's Lenvima from Cancer Drugs Fund in England  Pharma Letter2 weeks ago
[x]  

AbbVie, Eisai Company, And Obtain Additional Approval For New Dosing Regimen Of Fully Human Anti-TNF Monoclonal Antibody Humira In Patients With Crohn's Disease

- (ACN Newswire) - AbbVie GK (Headquarters: Tokyo, President: James Feliciano, "AbbVie"), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), and its subsidiary EA Pharma Co., Ltd. (Headquarters: Tokyo, CEO: Hajime Shimizu, "EA ...
 BioSpace1 month ago AbbVie, Eisai and EA Pharma receive additional approval for new Humira dosing regimen  Pharmaceutical Technology1 month ago EISAI : AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF Monoclonal Antibody Humira in Patients with Crohn's Disease  4 Traders1 month ago AbbVie, Eisai, EA Pharma obtain additional approval for...  Bio Spectrum Asia1 month ago
[x]  

Imaging Agents - Global Strategic Business Report

2 of 4 FEATURED COMPANIES Bracco Diagnostics, Inc. Eisai Co., Ltd. Eli Lilly and Company MORE I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations Disclaimers Data Interpretation & Reporting ...
 Research and Markets2 weeks ago Multiple Sclerosis Pipeline Review Report of 178 Companies  International Business Times1 week ago Global Tuberculosis Pipeline 2016 Market Report on 64 Companies  International Business Times1 month ago
[x]  
MyNewsDesk

Study Data from Eisai Update Understanding of Breast Cancer (Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin...

Study Data from Eisai Update Understanding of Breast Cancer (Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate) By a News Reporter-Staff News Editor at Women's Health Weekly -- Fresh data on Oncology are ...
 4 Traders3 weeks ago Higher Incidence and Rising Prevalence to Drive Breast Cancer Therapeutics Market to USD 12.8 Billion by 2020 - iHealthcareAnalyst, Inc.  BizWire Express2 weeks ago Acupressure reduced fatigue in breast cancer survivors  HealthMediciNet.com2 weeks ago Adaptive Randomization of Neratinib in Early Breast Cancer  New England Journal of Medicine2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - eisai
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less